COLORECTUM+ Digital System for Postoperative Quality Improvement in Colorectal Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRenJi Hospital

About this trial

This is a single-center, prospective, interventional study. A total of 236 colorectal cancer patients who underwent surgery will be enrolled and followed for 52 weeks. The digital healthcare quality management system, based on the COLORECTUM+ model, will be used for post-treatment quality evaluation and continuous improvement.

Patients will be managed using an Internet+ post-treatment healthcare management platform. The platform integrates AI technology for real-time symptom analysis and alerts. Patients will report symptoms and health data through the platform, which will generate alerts based on symptom severity to guide appropriate interventions. Follow-up assessments will include patient adherence, satisfaction, quality of life, and healthcare utilization.

The study expects to demonstrate that the digital healthcare quality management system improves follow-up rates, enhances patient adherence, reduces unplanned hospital visits, and increases overall patient satisfaction. The findings aim to provide evidence for the implementation of digital management systems in colorectal cancer post-treatment care, potentially leading to improved long-term outcomes for patients.

Eligibility criteria

Qualifiers

Over 18 years old.

Pathologically confirmed colorectal cancer patients.

Underwent surgery at the Colorectal Cancer Diagnosis and Treatment Center, Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine.

Signed informed consent form.

Disqualifiers

Unable to access electronic devices that can connect to the internet or mobile communications.

Uncontrolled psychiatric illness.

The ECOG score is greater than or equal to 3.

Deemed unsuitable for participation by the investigator.

Trial design

Treatments tested in this trial

  • Mobile application follow-up

Treatment groups

236 Participants
are divided into 1 treatment group

Sponsors and collaborators

RenJi Hospital

Lead sponsor

Shanghai Shen Kang Hospital Development Center

Collaborator